MLNM Millennium Pharmaceuticals (MM)

NEW YORK, May 6 /PRNewswire/ -- Mergent, Inc., administrator for the Healthshares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange Traded Funds, today announced the following changes with effect from the opening of trade on Friday, May 9, 2008: Masimo Corporation (NASDAQ:MASI) will replace Millennium Pharmaceuticals Inc (NASDAQ:MLNM) in the HealthShares(TM) Composite Index, Quest Diagnostics Inc (NYSE:DGX) will replace Millennium Pharmaceuticals Inc (NASDAQ:MLNM) in the HealthShares(TM) Enabling Technologies Index, Actelion (SWISS: ATLN) will replace Millennium Pharmaceuticals Inc (NASDAQ:MLNM) in the HealthShares(TM) Autoimmune-Inflammation Index, Fresenius SE (Frankfurt: FME) will replace Millennium Pharmaceuticals Inc (NASDAQ:MLNM) in the HealthShares(TM) Cancer Index, Actelion (SWISS: ATLN) will replace Millennium Pharmaceuticals Inc (NASDAQ:MLNM) in the HealthShares(TM) Cardiology Index, and Schwarz Pharma AG (Frankfurt: SRZ) will replace Millennium Pharmaceuticals Inc (NASDAQ:MLNM) in the HealthShares(TM) Neuroscience Index. Millennium is being acquired by Takeda Pharmaceutical Company Limited (Tokyo: 4502) through a cash tender offer. The HealthShares(TM) Composite Index consists of the 80 largest companies, by market capitalization, that are engaged in healthcare, life sciences and/or biotechnology that are part of the 16 underlying HealthShares(TM) Indexes, selecting the top 5 companies in market capitalization from each of the Composite Eligible Indexes. Companies included in the HealthShares(TM) Enabling Technologies Index provide technology products and/or services that enable and support the discovery, clinical development and manufacturing activities of pharmaceutical and biotechnology companies, including but not limited to genomics, proteomics, and high throughput screening. Companies included in the HealthShares(TM) Autoimmune-Inflammation Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of inflammatory diseases such as osteoarthritis and autoimmune disorders including, but not limited to, rheumatoid arthritis, allergies, multiple sclerosis, psoriasis and lupus. Companies included in the HealthShares(TM) Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. Companies included in the HealthShares(TM) Cardiology Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of cardiological indications including, but not limited to, atherosclerosis, coronary artery disease, congestive heart failure, stroke, hypertension, thrombosis, and restenosis. Companies included in the HealthShares(TM) Neuroscience Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders. About Mergent Mergent, Inc., a Xinhua Finance company (TSE Mothers: 9399; OTC ADRs: XHFNY), is the preferred provider of business and financial data on global publicly listed companies. Headquartered in Fort Mill, SC and New York City with sales offices in key North American cities, Mergent also has a strong global presence with offices in London, Shanghai, Tokyo, Toronto and Sydney. Mergent's databases contain detailed equity, debt and corporate action information on over 15,000 U.S. public companies, 20,000 non-U.S. public companies and all U.S. municipal bonds. For more than a century, Mergent has been providing solutions to clients in the investment management, academic, research and corporate information fields. Today, that unique experience is combined with leading-edge technology to form a robust, diverse product line that operates under Mergent's umbrella. These include Mergent's Dividend Achievers Indices -- the premier benchmark for long-term returns; Ford Equity Research -- a leading independent investment research firm; Mergent Online -- a powerful web-based research portal that provides critical business information to support daily research and analysis; Mergent Manuals, Handbooks and Investment Guides; in-depth municipal and corporate fixed-income data, as well as end-of-day evaluation pricing; EventsData -- providing real-time information on corporate actions, dividend payouts, news and updates directly to client desktops. For more information, please visit http://www.mergent.com/ and http://www.dividendachievers.com/. DATASOURCE: Mergent, Inc. CONTACT: Jean Dugan Director of Sales, Index Services Mergent, Inc., +1-212-413-7712, Web site: http://www.mergent.com/ http://www.dividendachievers.com/

Copyright